Frontiers in Pediatrics (Dec 2022)

Analysis of trio test in neurodevelopmental disorders

  • Se Hee Kim,
  • Soon Sung Kwon,
  • Joon Soo Lee,
  • Heung Dong Kim,
  • Seung-Tae Lee,
  • Jong Rak Choi,
  • Saeam Shin,
  • Hoon-Chul Kang

DOI
https://doi.org/10.3389/fped.2022.1073083
Journal volume & issue
Vol. 10

Abstract

Read online

BackgroundTrio test has been widely used for diagnosis of various hereditary disorders. We aimed to investigate the contribution of trio test in genetically diagnosing neurodevelopmental disorders (NDD).MethodsWe retrospectively reviewed 2,059 NDD cases with genetic test results. The trio test was conducted in 563 cases. Clinical usefulness, optimal timing, and methods for the trio test were reviewed.ResultsPathogenic or likely pathogenic variants were detected in 112 of 563 (19.9%) patients who underwent the trio test. With trio test results, the overall diagnostic yield increased by 5.4% (112/2,059). Of 165 de novo variants detected, 149 were pathogenic and we detected 85 novel pathogenic variants. Pathogenic, de novo variants were frequently detected in CDKL5, ATP1A3, and STXBP1.ConclusionThe trio test is an efficient method for genetically diagnosing NDD. We identified specific situations where a certain trio test is more appropriate, thereby providing a guide for clinicians when confronted with variants of unknown significance of specific genes.

Keywords